SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001558370-19-005053
Filing Date
2019-05-15
Accepted
2019-05-15 09:03:04
Documents
8
Period of Report
2018-12-31

Document Format Files

Seq Description Document Type Size
1 20-F/A f20-fa.htm 20-F/A 116298
2 EX-4.4 ex-4d4.htm EX-4.4 61873
3 EX-4.6 ex-4d6.htm EX-4.6 27165
4 EX-4.9 ex-4d9.htm EX-4.9 30891
5 EX-4.12 ex-4d12.htm EX-4.12 34759
6 EX-4.15 ex-4d15.htm EX-4.15 39106
7 EX-12.1 ex-12d1.htm EX-12.1 7175
8 EX-12.2 ex-12d2.htm EX-12.2 7196
  Complete submission text file 0001558370-19-005053.txt   325414
Mailing Address 21 HA'ARBA'A STREET TEL AVIV L3 64739
Business Address 21 HA'ARBA'A STREET TEL AVIV L3 64739 972-3-541-3131
RedHill Biopharma Ltd. (Filer) CIK: 0001553846 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3
Type: 20-F/A | Act: 34 | File No.: 001-35773 | Film No.: 19825318
SIC: 2834 Pharmaceutical Preparations